Atley intalls Atley C100 at UMC Utrecht, advancing At-211 clinical development in the Netherlands
Gothenburg, Sweden – 6 May 2025 – Atley Solutions has successfully installed an Atley C100 module at the University Medical Center Utrecht (UMC Utrecht), one of the Netherlands’ leading academic hospitals and a pioneering institution in translational cancer research. This marks the first Atley C100 installation in the Netherlands, expanding the European footprint of At-211 radiopharmaceutical manufacturing and underscoring UMC Utrecht’s leadership in next-generation targeted alpha therapy.
Empowering Scalable At-211 Radiopharmaceutical Manufacturing in the Netherlands
The Atley C100 is the world’s first and only commercially available manufacturing system specifically designed for At-211 radiopharmaceuticals. By automating both the dry distillation purification and radiolabeling processes, it offers standardized and reproducible radiopharmaceutical manufacturing, while ensuring scalability and operator safety.
UMC Utrecht to Launch Two Clinical Trials Using At-211 Radiopharmaceuticals
UMC Utrecht will use the Atley C100 module to support the clinical development of a portfolio of At-211-based radiopharmaceuticals. The institution has received funding for two clinical trials that will utilize the system: the first – in collaboration with the Princess Maxima Center for Pediatric Oncology – will evaluate [²¹¹At]mABG for the treatment of neuroblastoma, whilst the second – in collaboration with Telix Pharmaceuticals – will evaluate [²¹¹At]APA (TLX102) for glioblastoma. These studies aim to advance novel therapies for patients with limited treatment options, leveraging the precision and potency of At-211-based targeted alpha therapies. This marks the onset of a new era in nuclear medicine, wherein the therapeutic efficacy of At-211 is achieved with significantly reduced patient burden, including the mitigation of isolation requirements.
“Bringing the Atley C100 to Utrecht represents a key step in our mission to translate promising radiopharmaceuticals into clinical reality,” said Dr. Arthur Braat, Principal Investigator at UMC Utrecht. “We are excited to initiate our clinical programs using this technology and advance the field of At-211 therapy.”
“UMC Utrecht is a recognized leader in cancer research and nuclear medicine,” said Milton Lönnroth, CEO of Atley Solutions. “We are honoured to partner with them as they lead the charge in bringing At-211 radiopharmaceuticals to the clinic. This installation marks a significant milestone for both Atley and UMC Utrecht, enabling the hospital to transition seamlessly from preclinical research to clinical manufacturing and patient treatment.”
About Atley Solutions
Atley Solutions is the global leader in commercial products and services for the development, clinical evaluation and commercialisation of At-211 radiopharmaceuticals. The Atley C100 is the world’s only commercial module for automated manufacturing of At-211 radiopharmaceuticals, addressing key challenges in radionuclide production and supply chain scalability. In addition to its cutting-edge technology, Atley provides radiopharmaceutical development services and is a leading supplier of At-211.
About UMC Utrecht
UMC Utrecht is one of the largest public healthcare institutions in the Netherlands and a leading academic center for clinical research. With world-class expertise in oncology, neurology, and nuclear medicine, the institution is at the forefront of innovation in precision medicine. UMC Utrecht’s radiopharmaceutical research unit plays a key role in translating new therapies from bench to bedside, driving breakthroughs in targeted treatments for cancer and neurological diseases.
Contact Information
For more information about Atley Solutions or the Atley C100 please contact:
Milton Lönnroth
Co-Founder & CEO Atley Solutions AB
Phone: +46 (0) 704 34 84 57
Email: info@atley.com
